


MAY 2 3 2002

TECH CENTER 1600/2900

MACH2/CON



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner

Lisa B. Arthur

Group Art Unit:

1655

Applicants

Bernard F. Mach et al.

Application No.: 08/484,786

Confirmation No.: 4894

Filed

June 7, 1995

For

DNA SEQUENCES CODING FOR THE

DR β -CHAIN LOCUS OF THE HUMAN LYMPHOCYTE

ANTIGEN COMPLEX AND POLYPEPTIDES,

DIAGNOSTIC TYPING PROCESSES AND PRODUCTS

RELATED THERETO

New York, New York May 16, 2002

Hon. Commissioner for Patents

P.O. Box 2327

Arlington, Virginia 22202

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(c),

applicants make of record the following documents, copies of which are submitted herewith:

Articles

Kratzin, H. et al., PRIMARY STRUCTURE OF HUMAN HISTOCOMPATIBILITY ANTIGENS OF CLASS II, "PART I: Amino Acid Sequence of the N-terminal 198 Radicals of the B-chain of HLA-Dw2,2;DR2,2-Alloantigens," Hoppe-Seyler's Z. Physiol.

05/22/2002 MBERHE

00000075 08484786

180.00 OP

02 FC:126

Chem., 362:1665-1669 (1981). (Copies of the original version, in German along with an English-language translation, are enclosed.)

Abaza, M. I., et al., "Effects of Amino Acid Substitutions Outside an Antigenic Site on Protein Binding to Monoclonal Antibodies of Predetermined Specificity Obtained by Peptide Immunization: Demonstration with Region 94-100 (Antigenic Site3) of Myoglobin", Journal of Protein Chemistry, 11:433-444 (1992).

For the Examiner's convenience, the abovementioned documents are listed on the accompanying Form PTO-1449.

This Statement is submitted more than three months from the application filing date and after the mailing date of the first Office Action on the merits, but before the mailing date of either a final action under 37 C.F.R. § 1.113, or a notice of allowance under 37 C.F.R. § 1.311.

In accordance with 37 C.F.R. § 1.97, this Statement is accompanied by:

- [] a certification as required under 37 C.F.R.
 § 1.97(e)(1) or § 1.97(e)(2);
- [X] the fee as set forth in 37 C.F.R. § 1.17(p).

The Director is hereby authorized to charge payment of any additional fees required in connection with the accompanying Information Disclosure Statement, or credit any overpayment, to Deposit Account No. 06-1075. A duplicate copy of this letter is transmitted herewith.

Applicants respectfully request that the abovecited documents be (1) fully considered by the Examiner during the continued examination of this application and (2) printed on any patent issuing from this application. Applicants also request that a copy of the enclosed Form PTO-1449, duly initialed by the Examiner, be forwarded to the undersigned with the next communication.

Respectfully submitted,

Pierri (Reg. No. 30,709) Marga

Attorneys for Applicants

Shawn-Marie Mayrand (Reg. No. 48,986)

Agent for Applicants

c/o FISH & NEAVE

Customer No.: 1473

1251 Avenue of the Americas

New York, New York 10020-1104

Tel.: (212) 596-9000

Fax: (212) 596-9090

I Hereby Certify that this Correspondence is being Deposited with the U.S. Postal Service as First Class Mail in an Envelope Addressed to: COMMISSIONER FOR PATENTS P.O. Box 23.27

ARLINGTON VA 22202 on

Signature of Person Signing

May 16,2002